Armando Pérez de Prado

VerifyNow in acute coronary syndrome: design of the EPIC17-VERONICA trial to optimize platelet inhibition.

Introduction and objectives: De-escalation from prasugrel and ticagrelor to clopidogrel in patients undergoing percutaneous coronary intervention after acute coronary syndrome (ACS) is a strategy aimed at reducing bleeding. This study evaluates whether VerifyNow (Werfen, Spain)-g...